Recurrent Melanoma Active Not Recruiting Phase 1 Trials for Sorafenib (DB00398)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01303341Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or MelanomaTreatment